"Enolase1 (Eno1p) from C. albicans has been selected as a model antigenic protein to be displayed on the surfaces of S. cerevisiae cells. Eno1p has been identified as the group 5 in quantitative time-course proteome analyses. For a reason as same as Mdh1p in the previous section, Eno1p was although to be suitable for an antigen candidate of vaccine. Eno1p is also associated in an important metabolic pathway, glycolysis. To construct an oral vaccine, Eno1p was displayed on the yeast surface via introduction to the yeast strain Y4741 using the pULD1-eno1 plasmid; successful transformation was confirmed.
OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society. OMICS Group also organizing 3000+ International Scientific Conferences and events yearly all over the world with the support of 1000+ Scientific associations worldwide.
Citation: Shibasaki S, Karasaki M, Ueda M (2014) Combining Proteomic Strategies and Molecular Display Technology for Development of Vaccines against Candida albicans. J Proteomics Bioinform 7: 134-138."
Last date updated on April, 2021